HemoptysisCHORENCT07833878
Chinese Hemoptysis Registry Study
An observational study of Hemoptysis, run by Qiu Jipeng.
Trial summary
This is a prospective, multicenter, observational registry study of hemoptysis in China. Hospitalized patients with active hemoptysis who undergo vascular interventional diagnosis and therapy will be consecutively enrolled from tertiary hospitals across China. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hemoptysis
- What is being tested?
- Not applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study intervention
- How many people
- 2,500 participants
- Where
- No sites listed yet
- Study dates
- 10 Oct 2026to 31 Dec 2030
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Hospitalized adults with active hemoptysis undergoing vascular interventional diagnosis and therapy at tertiary hospitals with respiratory interventional capability in China
Who may be able to join
- Age ≥18 years.
- Clinically confirmed active hemoptysis, with a pulmonary bleeding lesion verified by chest CT/CTA, bronchoscopy, or angiography.
- Hemoptysis volume >100 mL in a single episode or >300 mL per day, refractory to medical treatment.
- Undergoing vascular interventional diagnosis and therapy.
- Able to provide written informed consent and willing to participate voluntarily.
Who cannot join
- Concurrent participation in an interventional clinical trial of an investigational drug or novel interventional device.
- Missing contact information or inability to complete basic follow-up within 3 months (very high risk of loss to follow-up).
- Bleeding originating from the upper gastrointestinal tract (hematemesis) or upper respiratory tract (nasopharyngeal bleeding).
- Severe, uncorrectable coagulopathy that is an absolute contraindication to interventional procedures.
- Known allergy to iodinated contrast agents.
- Pregnancy or lactation.
- Severe hepatic or renal dysfunction precluding tolerance of interventional procedures.
- Any other condition judged by the investigator as inappropriate for participation.
About this study
Official title: A Prospective, Multicenter, Observational Registry Study of the Etiology Spectrum, Interventional Management, and Long-term Outcomes of Hemoptysis in China
This is a prospective, multicenter, observational registry study of hemoptysis in China. Hospitalized patients with active hemoptysis who undergo vascular interventional diagnosis and therapy will be consecutively enrolled from tertiary hospitals across China. Baseline clinical, imaging, angiographic, procedural, and in-hospital outcome data will be collected, and patients will be followed at 1 and 3 months and every 6 months for at least 2 years. The study aims to describe the real-world epidemiology and etiology spectrum of hemoptysis in China, evaluate short- and long-term outcomes of interventional therapy, identify independent risk factors for recurrence, and build a recurrence prediction model to support standardized diagnosis and treatment of hemoptysis.
Read the detailed description
Background: Hemoptysis is one of the most common respiratory emergencies, with a mortality of over 75% for massive hemoptysis when untreated. Bronchial artery embolization and other vascular interventions have become first-line therapy, with immediate hemostasis rates of 70-99%. However, no nationwide standardized multicenter registry for hemoptysis exists in China; the epidemiological characteristics, etiology spectrum, individualized interventional strategies, long-term prognosis, and recurrence mechanisms of Chinese patients with hemoptysis remain unclear.
Objectives: (1) To describe the cross-sectional etiology spectrum and epidemiological characteristics of hemoptysis in China; (2) to evaluate the immediate and long-term efficacy of vascular interventional therapy, including immediate hemostasis success rate, clinical success rate, and long-term recurrence rate across different etiologies; (3) to identify independent risk factors for post-interventional recurrence using Cox regression and construct a nomogram prediction model; (4) to validate the clinical value of the "systemic-to-pulmonary shunt" hypothesis in interventional management of hemoptysis; (5) to provide high-quality evidence for standardization of interventional diagnosis and treatment of hemoptysis.
Methods: Consecutively hospitalized patients aged ≥18 years with active hemoptysis (>100 mL in a single episode or >300 mL/day) refractory to medical treatment, confirmed by chest CT/CTA, bronchoscopy, or angiography, and undergoing vascular interventional diagnosis and therapy will be enrolled. A minimum of 2500 patients will be enrolled over approximately 4 years (September 2026 to December 2030). Follow-up visits are scheduled at 1 and 3 months after discharge and every 6 months thereafter for at least 2 years, recording hemoptysis recurrence, intervention-related complications, all-cause and hemoptysis-specific death.
- Conditions
- Hemoptysis
- Being tested
- Not applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study intervention
- Keywords
- bronchial artery embolization, hemoptysis recurrence, nterventional pulmonology, egistry
- Medical subject headings
- Hemoptysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Not applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study interventionOther
Not applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study interventions by the investigator.
What is being measured
The primary outcome is the main question the study is designed to answer.
Hemoptysis recurrence within 2 years
Time to and incidence of hemoptysis recurrence (re-bleeding requiring medical attention) within 2 years after enrollment, assessed by telephone or outpatient follow-up every 6 months.
Measured: Through 2 years after enrollment.
Hemoptysis-specific mortality
Death attributable to hemoptysis (e.g., asphyxia or hemorrhagic shock due to pulmonary bleeding) within 2 years after enrollment.
Measured: Through 2 years after enrollment.
All-cause mortality
Death from any cause within 2 years after enrollment.
Measured: Through 2 years after enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start10 Oct 2026 (estimated)
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HemoptysisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,500 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Qiu Jipeng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Qiu Jipeng, Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07833878
- Sponsor's protocol ID
- JHCH-HEMOPTYSIS-2026
- Acronym
- CHORE
- Status last verified
- Oct 2026
- First submitted
- 16 Sep 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter, Observational Registry Study of the Etiology Spectrum, Interventional Management, and Long-term Outcomes of Hemoptysis in China
- ClinicalTrials.gov ID
- NCT07833878
- Acronym / sponsor ID
- CHORE / JHCH-HEMOPTYSIS-2026
- Conditions
- Hemoptysis
- Keywords
- bronchial artery embolization, hemoptysis recurrence, nterventional pulmonology, egistry
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Qiu JipengUniversity, hospital or other
- Study start
- 10 Oct 2026 (estimated)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, multicenter, observational registry study of hemoptysis in China. Hospitalized patients with active hemoptysis who undergo vascular interventional diagnosis and therapy will be consecutively enrolled from tertiary hospitals across China. Baseline clinical, imaging, angiographic, procedural, and in-hospital outcome data will be collected, and patients will be followed at 1 and 3 months and every 6 months for at least 2 years. The study aims to describe the real-world epidemiology and etiology spectrum of hemoptysis in China, evaluate short- and long-term outcomes of interventional therapy, identify independent risk factors for recurrence, and build a recurrence prediction model to support standardized diagnosis and treatment of hemoptysis.
Detailed description
Background: Hemoptysis is one of the most common respiratory emergencies, with a mortality of over 75% for massive hemoptysis when untreated. Bronchial artery embolization and other vascular interventions have become first-line therapy, with immediate hemostasis rates of 70-99%. However, no nationwide standardized multicenter registry for hemoptysis exists in China; the epidemiological characteristics, etiology spectrum, individualized interventional strategies, long-term prognosis, and recurrence mechanisms of Chinese patients with hemoptysis remain unclear.
Objectives: (1) To describe the cross-sectional etiology spectrum and epidemiological characteristics of hemoptysis in China; (2) to evaluate the immediate and long-term efficacy of vascular interventional therapy, including immediate hemostasis success rate, clinical success rate, and long-term recurrence rate across different etiologies; (3) to identify independent risk factors for post-interventional recurrence using Cox regression and construct a nomogram prediction model; (4) to validate the clinical value of the "systemic-to-pulmonary shunt" hypothesis in interventional management of hemoptysis; (5) to provide high-quality evidence for standardization of interventional diagnosis and treatment of hemoptysis.
Methods: Consecutively hospitalized patients aged ≥18 years with active hemoptysis (>100 mL in a single episode or >300 mL/day) refractory to medical treatment, confirmed by chest CT/CTA, bronchoscopy, or angiography, and undergoing vascular interventional diagnosis and therapy will be enrolled. A minimum of 2500 patients will be enrolled over approximately 4 years (September 2026 to December 2030). Follow-up visits are scheduled at 1 and 3 months after discharge and every 6 months thereafter for at least 2 years, recording hemoptysis recurrence, intervention-related complications, all-cause and hemoptysis-specific death.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Hospitalized adults with active hemoptysis undergoing vascular interventional diagnosis and therapy at tertiary hospitals with respiratory interventional capability in China
Key inclusion criteria (5 listed)
- Age ≥18 years.
- Clinically confirmed active hemoptysis, with a pulmonary bleeding lesion verified by chest CT/CTA, bronchoscopy, or angiography.
- Hemoptysis volume >100 mL in a single episode or >300 mL per day, refractory to medical treatment.
- Undergoing vascular interventional diagnosis and therapy.
- Able to provide written informed consent and willing to participate voluntarily.
Key exclusion criteria (8 listed)
- Concurrent participation in an interventional clinical trial of an investigational drug or novel interventional device.
- Missing contact information or inability to complete basic follow-up within 3 months (very high risk of loss to follow-up).
- Bleeding originating from the upper gastrointestinal tract (hematemesis) or upper respiratory tract (nasopharyngeal bleeding).
- Severe, uncorrectable coagulopathy that is an absolute contraindication to interventional procedures.
- Known allergy to iodinated contrast agents.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Not applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study interventionNot applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study interventions by the investigator. | Other | – |
Primary outcome
Hemoptysis recurrence within 2 years
Time frame: Through 2 years after enrollment.
Time to and incidence of hemoptysis recurrence (re-bleeding requiring medical attention) within 2 years after enrollment, assessed by telephone or outpatient follow-up every 6 months.
Hemoptysis-specific mortality
Time frame: Through 2 years after enrollment.
Death attributable to hemoptysis (e.g., asphyxia or hemorrhagic shock due to pulmonary bleeding) within 2 years after enrollment.
All-cause mortality
Time frame: Through 2 years after enrollment.
Death from any cause within 2 years after enrollment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Related trials for Hemoptysis
Enrolling by invitationPhase 4
Comparison Between Efficacy of Inhaled VS Intravenous Tranexamic Acid for Hemoptysis
Hemoptysis
RecruitingObservational study
Tracheal Cuff Pressure and Postoperative Complications
Tracheal Intubation, Postoperative Complications (Cardiopulmonary)
Not yet recruitingObservational study
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
Hemorrhage, Gastrointestinal Hemorrhage
Not yet recruitingPhase 3
Nebulized Versus Intravenous Tranexamic Acid for Hemoptysis
Hemoptysis, Pulmonary Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemoptysis, run by Qiu Jipeng.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hemoptysis recurrence within 2 years (time frame: Through 2 years after enrollment.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.